Corvus Pharmaceuticals Income Statement (2015-2026) | CRVS

Income Statement Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating items
Research & Development (Quarter)
6.99M4.79M5.10M4.92M10.37M4.08M4.59M3.97M3.96M4.00M0.67M4.11M5.22M7.45M7.87M8.45M5.04M15.96M
Selling, General & Administrative (Quarter)
2.06M2.02M2.31M2.09M2.11M1.59M1.98M1.65M1.59M1.65M2.18M1.82M2.03M2.47M2.39M2.12M3.70M3.33M
Restructuring Costs (Quarter)
0.99M0.55M0.78M0.95M0.85M0.62M1.92M4.15M
Other Operating Expenses (Quarter)
2.42M-0.55M-0.78M-0.95M-0.85M-0.62M4.21M-4.15M
Operating Expenses (Quarter)
9.05M6.81M7.41M7.01M12.47M5.67M6.57M5.62M5.56M5.65M6.25M5.93M7.25M9.92M10.26M10.57M14.88M19.30M
Operating Income (Quarter)
-9.05M-6.81M-7.41M-7.01M-12.47M-5.67M-6.57M-5.62M-5.56M-5.65M-6.25M-5.93M-7.25M-9.92M-10.26M-10.57M-14.88M-19.30M
EBIT (Quarter)
-9.05M-6.81M-7.41M-7.01M-12.47M-5.67M-6.57M-5.62M-5.56M-5.65M-6.25M-5.93M-7.25M-9.92M-10.26M-10.57M-14.88M-19.30M
Non-operating items
Interest & Investment Income (Quarter)
-0.01M-0.01M0.01M0.10M0.23M0.32M0.38M0.40M0.42M0.38M0.32M0.43M0.57M0.53M0.64M0.74M1.78M2.05M
Non Operating Income (Quarter)
25.11M1.19M1.34M
Net income details
EBT (Quarter)
-9.47M-7.22M-7.83M-7.35M-12.68M-5.78M-6.14M-5.22M-5.13M-5.73M-5.94M-3.69M-39.53M15.73M-7.61M-9.83M-13.09M-17.25M
Profit After Tax (Quarter)
-10.69M-10.57M-8.30M-8.36M-14.83M-6.75M-7.87M-6.50M-6.00M-5.74M-5.70M-4.26M-39.60M15.23M-8.00M-10.16M-13.92M-18.13M
Equity Income (Quarter)
-1.71M-2.56M-1.04M-1.60M-2.73M-4.64M-1.73M-1.28M-0.86M-1.40M
Income from Non-Controlling Interests (Quarter)
-0.00M-0.00M-0.03M-0.05M0.01M0.03M0.04M-0.00M0.01M0.02M-0.01M0.01M0.15M-0.02M-0.02M0.03M-0.33M-0.49M
Income from Continuing Operations (Quarter)
-9.47M-7.22M-7.83M-7.35M-12.68M-5.78M-6.14M-5.22M-5.13M-5.73M-5.94M-3.69M-39.53M15.73M-7.61M-9.83M-13.09M-17.25M
Consolidated Net Income (Quarter)
-9.47M-7.22M-7.83M-7.35M-12.68M-5.78M-6.14M-5.22M-5.13M-5.73M-5.94M-3.69M-39.53M15.73M-7.61M-9.83M-13.09M-17.25M
Income towards Parent Company (Quarter)
-9.47M-7.22M-7.83M-7.35M-12.68M-5.78M-6.14M-5.22M-5.13M-5.73M-5.94M-3.69M-39.53M15.73M-7.61M-9.83M-13.09M-17.25M
Net Income towards Common Stockholders (Quarter)
-9.47M-7.22M-7.83M-7.35M-12.68M-5.78M-6.14M-5.22M-5.13M-5.73M-5.94M-3.69M-39.53M15.73M-7.61M-9.83M-13.09M-17.25M
Additional items
EPS (Basic) (Quarter)
-0.22-0.17-0.17-0.16-0.27-0.12-0.13-0.11-0.10-0.12-0.12-0.06-0.590.22-0.10-0.12-0.15-0.19
EPS (Diluted) (Quarter)
-0.22-0.17-0.17-0.16-0.27-0.12-0.13-0.11-0.10-0.12-0.12-0.06-0.590.21-0.10-0.12-0.15-0.19
Shares Outstanding (Quarter)
43.95M41.85M46.55M46.55M46.55M46.55M46.56M47.50M48.97M48.03M49.04M59.71M66.70M60.99M72.13M77.77M82.84M78.96M90.00M92.37M
Shares Outstanding (Diluted) (Quarter)
43.95M41.85M46.55M46.55M46.55M46.55M46.56M47.50M48.97M48.03M49.04M59.71M66.70M60.99M75.15M77.77M82.84M79.74M90.00M92.37M
Shares Outstanding (Entity) (Quarter)
46.55M46.55M46.55M46.55M46.55M46.55M46.57M48.90M49.04M49.04M49.04M62.55M62.58M67.90M68.17M74.51M74.68M74.70M84.09M84.12M
EBITDA (Quarter)
-9.05M-6.81M-7.41M-7.01M-12.47M-5.67M-6.57M-5.62M-5.56M-5.65M-6.25M-5.93M-7.25M-9.92M-10.26M-10.57M-14.88M-19.30M
Interest Expenses (Quarter)
0.41M0.41M0.43M0.43M0.43M0.43M0.46M0.46M0.46M0.46M1.07M0.72M0.36M-1.27M0.57M0.17M0.57M0.02M0.92M0.80M